News

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best medical stocks to invest in according to billionaires. Intuitive Surgical, Inc. (NASDAQ:ISRG) announced on May 21 several recent and upcoming innovations, which included enhancements across da Vinci 5 and its supporting ecosystem, advancements designed to enhance product and instrument security and reliability, and extended‑use Force Feedback instruments. Management stated […]

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best robotic surgery stocks to buy. BofA cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $520 from $650 on May 18, reiterating a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies the week before in Las Vegas, it […]

ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.

Over the last six months, Intuitive Surgical’s shares have sunk to $442.32, producing a disappointing 19.9% loss - a stark contrast to the S&P 500’s 13.2% gain. This might have investors contemplating their next move.

Intuitive Surgical (NasdaqGS:ISRG) has outlined more than 100 new features coming to its da Vinci 5 surgical platform. Key additions include extended-use Force Feedback instruments, security and reliability upgrades, and telepresence tools for remote collaboration. The company expects these updates to broaden the platform’s capabilities in minimally invasive robotic surgery and support surgeon autonomy. For investors watching NasdaqGS:ISRG at a share price of $439.8, this product update...

While Intuitive Surgical has notably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.8% has lagged the S&P 500’s 13.2% climb.

Intuitive Surgical’s da Vinci 5 surgical platform, which began shipping in earnest on April 1, 2026, runs on 10,000 times the computing power of the da Vinci Xi and was co-engineered with NVIDIA’s Isaac platform. That is a working hospital robot, on the floor, today, that needed an AI compute stack nobody had five years ... Quantum Computing and Robotics Are Arriving Faster Than Most Investors Realize and After Years of Covering This Space These 3 ETFs Stand Out

It'd be a mistake to overlook these stocks, despite their recent challenges.

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?

Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]

Boston Scientific (BSX) stock declined 47% over the last 12 months to trade near $57. Despite total revenues growing 17.4% to $20.6 billion and net income margins improving to 17.3%, the P/E multiple contracted by 70%. The selloff was triggered by a Q4 2025 GAAP EPS miss and a significant full-year 2026 organic growth guidance cut. The company's management lowered the target from a 10 to 11% range down to 6.5 to 8.0%, attributing the reset to greater-than-expected market share loss in the Electr

Everyone is still glued to Tesla (NASDAQ:TSLA) because a Q1 earnings beat, the robotaxi pitch, and the Optimus humanoid tease have convinced retail traders the autonomy story finally pays off this year. The Tesla Trade Is Crowded and Priced for a Miracle Tesla carries a P/E of 406 and a free cash flow yield of ... Forget Tesla. The Robotics Company Actually Shipping Revenue Has a $22 Billion Backlog and Nobody Is Talking About It

Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Recent performance context for Intuitive Surgical Intuitive Surgical (ISRG) has been under pressure recently, with the stock down about 10% over the past month and about 15% over the past 3 months. This has prompted investors to reassess expectations. See our latest analysis for Intuitive Surgical. Beyond the recent pullback, the stock has also declined about 25% based on the year to date share price return, even though the 3 year and 5 year total shareholder returns remain positive. If you...

Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics. That flywheel is the moat. The three companies owning the installed bases to build it are Intuitive Surgical (NASDAQ: ISRG), Medtronic (NYSE: MDT), and ... Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays

Intuitive Surgical is in its own bear market, which has historically been a good time for aggressive growth investors to buy.

ISRG's da Vinci 5 is driving stronger utilization and procedure growth, but can higher throughput and after-hours surgeries sustain momentum?

With an upside potential of 35.5%, Intuitive Surgical, Inc. (NASDAQ:ISRG) remains a bullish pick among analysts. The stock, therefore, earns its place on our list of the best agentic AI stocks to buy right now. On April 21, 2026, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported strong first-quarter results, exceeding Wall Street projections in both revenue and […]

Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]

ISRG nears a key support level after a 23.7% YTD drop, but strong da Vinci 5 adoption and procedure growth may fuel a rebound.

In recent months, Intuitive Surgical has faced FDA Class I recalls on certain da Vinci stapler components and visible institutional selling, reflecting elevated concern around product safety and regulatory scrutiny despite earlier strong quarterly results. These developments coincide with ongoing competition in surgical robotics and highlight how regulatory risk and large investor behavior can quickly influence perceptions of an otherwise growing, cash-generative business model. We’ll now...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

The heavy selling pressure might have exhausted for Intuitive Surgical (ISRG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Many investors understandably have doubts about the company right now.

Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Wondering if Intuitive Surgical at around US$453 per share is still worth your attention, or if the stock price already reflects most of the opportunity? The stock has been relatively flat over the past week with a 0.9% decline and is roughly unchanged over 30 days. Year to date it is down 19.3%, the 1 year return sits at a 15.7% decline, and the 3 year and 5 year returns are 49.4% and 65.8% respectively. Recent share price moves come as investors continue to assess the company's position in...

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio. Chairman, Chief Executive Officer a